Obesity (Silver Spring, Md.)

Testing oral GLP-1RA TERN-601 in adults with obesity or overweight: early phase placebo-controlled studies with increasing doses

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

The safety and tolerability of TERN-601, a once-daily oral medication, were assessed in Phase 1 and 2 clinical studies.

  • TERN-601 is a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
  • Phase 1 and 2 clinical studies focused on safety and tolerability.
  • Pharmacokinetics and efficacy were also evaluated in these studies.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Jun '25
Safety, body responses, and drug behavior of amycretin, a new combined GLP-1 and amylin receptor medicine, in a first human trial
top 1% journal
cited by 25 papers
randomized controlled trial
Jun '26
Elecoglipron, an oral drug activating GLP-1 receptors, tested in adults with obesity or overweight in a phase 2 clinical trial
top 1% journal
cited by 1 paper
journal article
Nov '22
LY3437943, a new drug activating three hormone receptors, tested in people with type 2 diabetes in a controlled early-stage trial with increasing doses
top 1% journal
cited by 176 papers
randomized controlled trial
Oct '24
Testing different doses of the oral drug lotiglipron for type 2 diabetes and obesity in a controlled trial
top 5% journal
cited by 26 papers
randomized controlled trial
Jun '26
Elecoglipron, an oral drug activating GLP-1 receptors, tested in adults with type 2 diabetes in a multi-center phase 2b placebo-controlled trial
top 1% journal
cited by 1 paper
journal article
Oct '22
Safety and effectiveness of the combined GLP-1 and glucagon drug mazdutide (9 mg and 10 mg) in Chinese adults with overweight or obesity: a controlled early-phase trial
top 2% journal
cited by 69 papers
journal article
Sep '23
Weight loss and safety of NNC9204-1177, a drug acting on glucagon and GLP-1 receptors, in adults with overweight or obesity from three early trials
top 5% journal
cited by 40 papers
randomized controlled trial
Sep '25
Safety and body effects of the oral drug DA-302168S in healthy and overweight adults
top 5% journal
randomized controlled trial
Jun '25
Effectiveness and safety of danuglipron at different doses in adults with obesity
top 5% journal
cited by 19 papers
randomized controlled trial

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief